Relay Therapeutics, Inc. - Common Stock, par value $0.0001 per share (RLAY)

Historical Holders from Q3 2020 to Q3 2025

Symbol
RLAY on Nasdaq
Type / Class
Equity / Common Stock, par value $0.0001 per share
Shares outstanding
172M
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares, excl. options
166M
Holdings value
$868M
% of all portfolios
0.002%
Grand Portfolio weight change
0%
Number of holders
196
Number of buys
82
Number of sells
-87
Average Value change %
0%
Average buys %
+0%
Average sells %
0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Relay Therapeutics, Inc. - Common Stock, par value $0.0001 per share (RLAY)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Commodore Capital LP 9.9% +26.3% $88.7M $19.1M 17M +27.3% Commodore Capital LP 30 Sep 2025
Point72 Asset Management, L.P. 7.8% +35% $50.2M $14M 13.4M +38.7% Point72 Asset Management, L.P. 30 Jun 2025
BlackRock, Inc. 6.1% -30% $32.9M -$13.9M 10.3M -29.8% BlackRock, Inc. 31 Mar 2025
VANGUARD GROUP INC 5.47% -23.9% $32.5M -$9.43M 9.38M -22.5% The Vanguard Group 30 Jun 2025

Institutional Holders of Relay Therapeutics, Inc. - Common Stock, par value $0.0001 per share (RLAY)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 166M $868M -$18.5M $5.22 196
2025 Q2 171M $591M +$36.2M $3.46 203
2025 Q1 163M $426M -$16.3M $2.62 205
2024 Q4 164M $675M -$42.4M $4.12 197
2024 Q3 163M $1.16B +$253M $7.08 193
2024 Q2 127M $826M -$42.4M $6.52 171
2024 Q1 132M $1.1B +$24.6M $8.30 182
2023 Q4 127M $1.4B -$17.1M $11.01 176
2023 Q3 130M $1.1B -$2.92M $8.41 169
2023 Q2 129M $1.62B -$20.8M $12.56 159
2023 Q1 131M $2.16B +$53.2M $16.47 155
2022 Q4 128M $1.92B +$58.9M $14.94 163
2022 Q3 124M $2.76B +$25.5M $22.37 153
2022 Q2 121M $2.02B +$125M $16.75 137
2022 Q1 113M $3.38B +$67.7M $29.93 133
2021 Q4 111M $3.41B +$589M $30.71 128
2021 Q3 91.8M $2.89B +$74.3M $31.53 132
2021 Q2 89.1M $3.26B +$138M $36.59 124
2021 Q1 85.5M $2.96B -$171M $34.57 135
2020 Q4 87.7M $3.64B +$108M $41.56 115
2020 Q3 84.7M $3.6B +$3.6B $42.59 94